Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.

Morency D, Dumitra S, Parvez E, Martel K, Basik M, Robidoux A, Poirier B, Holloway CMB, Gaboury L, Sideris L, Meterissian S, Boileau JF.

Ann Surg Oncol. 2019 Dec;26(13):4337-4345. doi: 10.1245/s10434-019-07809-7. Epub 2019 Oct 11.

PMID:
31605348
2.

A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.

Sirois I, Aguilar-Mahecha A, Lafleur J, Fowler E, Vu V, Scriver M, Buchanan M, Chabot C, Ramanathan A, Balachandran B, Légaré S, Przybytkowski E, Lan C, Krzemien U, Cavallone L, Aleynikova O, Ferrario C, Guilbert MC, Benlimame N, Saad A, Alaoui-Jamali M, Saragovi HU, Josephy S, O'Flanagan C, Hursting SD, Richard VR, Zahedi RP, Borchers CH, Bareke E, Nabavi S, Tonellato P, Roy JA, Robidoux A, Marcus EA, Mihalcioiu C, Majewski J, Basik M.

Mol Cancer Res. 2019 Dec;17(12):2492-2507. doi: 10.1158/1541-7786.MCR-19-0264. Epub 2019 Sep 19.

PMID:
31537618
3.

Metastatic Breast Carcinoma-Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression.

Gui Y, Aguilar-Mahecha A, Krzemien U, Hosein A, Buchanan M, Lafleur J, Pollak M, Ferrario C, Basik M.

Clin Cancer Res. 2019 Dec 1;25(23):7229-7242. doi: 10.1158/1078-0432.CCR-19-1268. Epub 2019 Sep 12.

PMID:
31515454
4.

Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report.

Aguilar-Mahecha A, Joseph S, Cavallone L, Buchanan M, Krzemien U, Batist G, Basik M.

Front Oncol. 2019 Aug 6;9:698. doi: 10.3389/fonc.2019.00698. eCollection 2019.

5.

An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.

Smith HW, Hirukawa A, Sanguin-Gendreau V, Nandi I, Dufour CR, Zuo D, Tandoc K, Leibovitch M, Singh S, Rennhack JP, Swiatnicki M, Lavoie C, Papavasiliou V, Temps C, Carragher NO, Unciti-Broceta A, Savage P, Basik M, van Hoef V, Larsson O, Cooper CL, Vargas Calderon AC, Beith J, Millar E, Selinger C, Giguère V, Park M, Harris LN, Varadan V, Andrechek ER, O'Toole SA, Topisirovic I, Muller WJ.

Nat Commun. 2019 Jul 1;10(1):2901. doi: 10.1038/s41467-019-10681-4.

6.

Identification of a Radiosensitivity Molecular Signature Induced by Enzalutamide in Hormone-sensitive and Hormone-resistant Prostate Cancer Cells.

Ghashghaei M, Niazi TM, Aguilar-Mahecha A, Klein KO, Greenwood CMT, Basik M, Muanza TM.

Sci Rep. 2019 Jun 20;9(1):8838. doi: 10.1038/s41598-019-44991-w.

7.

An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy.

Darini C, Ghaddar N, Chabot C, Assaker G, Sabri S, Wang S, Krishnamoorthy J, Buchanan M, Aguilar-Mahecha A, Abdulkarim B, Deschenes J, Torres J, Ursini-Siegel J, Basik M, Koromilas AE.

Nat Commun. 2019 May 13;10(1):2139. doi: 10.1038/s41467-019-10138-8.

8.

A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.

Cavallone L, Aldamry M, Lafleur J, Lan C, Gonzalez Ginestet P, Alirezaie N, Ferrario C, Aguilar-Mahecha A, Basik M.

Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):909-916. doi: 10.1158/1055-9965.EPI-18-0586. Epub 2019 Mar 1.

PMID:
30824523
9.

Gender differences in how physicians access and process information.

Gotlieb R, Abitbol J, How JA, Ben-Brith I, Abenhaim HA, Lau SK, Basik M, Rosberger Z, Geva N, Gotlieb WH, Mintz A.

Gynecol Oncol Rep. 2019 Jan 2;27:50-53. doi: 10.1016/j.gore.2018.12.008. eCollection 2019 Feb. Review.

10.

MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ.

Guo Q, Li VZ, Nichol JN, Huang F, Yang W, Preston SEJ, Talat Z, Lefrère H, Yu H, Zhang G, Basik M, Gonçalves C, Zhan Y, Plourde D, Su J, Torres J, Marques M, Habyan SA, Bijian K, Amant F, Witcher M, Behbod F, McCaffrey L, Alaoui-Jamali M, Giannakopoulos NV, Brackstone M, Postovit LM, Del Rincón SV, Miller WH Jr.

Cancer Res. 2019 Apr 1;79(7):1646-1657. doi: 10.1158/0008-5472.CAN-18-1602. Epub 2019 Jan 18.

11.

Leukocytes as a reservoir of circulating oncogenic DNA and regulatory targets of tumor-derived extracellular vesicles.

Chennakrishnaiah S, Meehan B, D'Asti E, Montermini L, Lee TH, Karatzas N, Buchanan M, Tawil N, Choi D, Divangahi M, Basik M, Rak J.

J Thromb Haemost. 2018 Sep;16(9):1800-1813. doi: 10.1111/jth.14222. Epub 2018 Aug 16.

PMID:
29971917
12.

Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program.

Hirukawa A, Smith HW, Zuo D, Dufour CR, Savage P, Bertos N, Johnson RM, Bui T, Bourque G, Basik M, Giguère V, Park M, Muller WJ.

Nat Commun. 2018 Jun 29;9(1):2547. doi: 10.1038/s41467-018-04864-8.

13.

Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry.

Mnatsakanyan R, Shema G, Basik M, Batist G, Borchers CH, Sickmann A, Zahedi RP.

Expert Rev Proteomics. 2018 Jun;15(6):515-535. doi: 10.1080/14789450.2018.1483340.

PMID:
29893147
14.

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.

Goyette MA, Duhamel S, Aubert L, Pelletier A, Savage P, Thibault MP, Johnson RM, Carmeliet P, Basik M, Gaboury L, Muller WJ, Park M, Roux PP, Gratton JP, Côté JF.

Cell Rep. 2018 May 1;23(5):1476-1490. doi: 10.1016/j.celrep.2018.04.019.

15.

How iMALDI can improve clinical diagnostics.

Popp R, Basik M, Spatz A, Batist G, Zahedi RP, Borchers CH.

Analyst. 2018 May 15;143(10):2197-2203. doi: 10.1039/c8an00094h. Review.

PMID:
29713694
16.

The crosstalk between breast carcinoma-associated fibroblasts and cancer cells promotes RhoA-dependent invasion via IGF-1 and PAI-1.

Daubriac J, Han S, Grahovac J, Smith E, Hosein A, Buchanan M, Basik M, Boucher Y.

Oncotarget. 2017 Dec 28;9(12):10375-10387. doi: 10.18632/oncotarget.23735. eCollection 2018 Feb 13.

17.

A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.

Savage P, Blanchet-Cohen A, Revil T, Badescu D, Saleh SMI, Wang YC, Zuo D, Liu L, Bertos NR, Munoz-Ramos V, Basik M, Petrecca K, Asselah J, Meterissian S, Guiot MC, Omeroglu A, Kleinman CL, Park M, Ragoussis J.

Cell Rep. 2017 Oct 31;21(5):1140-1149. doi: 10.1016/j.celrep.2017.10.015.

18.

SPEN, a new player in primary cilia formation and cell migration in breast cancer.

Légaré S, Chabot C, Basik M.

Breast Cancer Res. 2017 Sep 6;19(1):104. doi: 10.1186/s13058-017-0897-3.

19.

Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits.

Alcaide M, Yu S, Davidson J, Albuquerque M, Bushell K, Fornika D, Arthur S, Grande BM, McNamara S, Tertre MCD, Batist G, Huntsman DG, Cavallone L, Aguilar A, Basik M, Johnson NA, Deyell RJ, Rassekh SR, Morin RD.

Sci Rep. 2017 Sep 5;7(1):10574. doi: 10.1038/s41598-017-10269-2.

20.

Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors.

Popp R, Li H, LeBlanc A, Mohammed Y, Aguilar-Mahecha A, Chambers AG, Lan C, Poetz O, Basik M, Batist G, Borchers CH.

Anal Chem. 2017 Oct 3;89(19):10592-10600. doi: 10.1021/acs.analchem.7b02934. Epub 2017 Sep 20.

PMID:
28853539
21.

Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials.

Kuerer HM, Vrancken Peeters MTFD, Rea DW, Basik M, De Los Santos J, Heil J.

Ann Surg Oncol. 2017 Oct;24(10):2855-2862. doi: 10.1245/s10434-017-5926-z. Epub 2017 Aug 1.

PMID:
28766204
22.

The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.

Aguilar-Mahecha A, Lafleur J, Pelmus M, Seguin C, Lan C, Discepola F, Kovacina B, Christodoulopoulos R, Salvucci O, Mihalcioiu C, Roy JA, Robidoux A, Marcus EA, Batist G, Basik M.

Mod Pathol. 2017 Nov;30(11):1567-1576. doi: 10.1038/modpathol.2017.82. Epub 2017 Jul 28.

23.

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.

Johnston S, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, Dreosti L, Mann H, Stuart M, Cristofanilli M.

Breast Cancer Res Treat. 2016 Nov;160(1):91-99. Epub 2016 Sep 21.

PMID:
27654971
24.

Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.

Légaré S, Basik M.

Mol Endocrinol. 2016 Sep;30(9):965-76. doi: 10.1210/me.2016-1072. Epub 2016 Jul 20. Review.

25.

PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.

Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, Jones RG, Siegel PM.

Cell Metab. 2015 Oct 6;22(4):577-89. doi: 10.1016/j.cmet.2015.08.007. Epub 2015 Sep 10.

26.

The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.

Légaré S, Cavallone L, Mamo A, Chabot C, Sirois I, Magliocco A, Klimowicz A, Tonin PN, Buchanan M, Keilty D, Hassan S, Laperrière D, Mader S, Aleynikova O, Basik M.

Cancer Res. 2015 Oct 15;75(20):4351-63. doi: 10.1158/0008-5472.CAN-14-3475. Epub 2015 Aug 21.

27.

A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer.

Hosein AN, Livingstone J, Buchanan M, Reid JF, Hallett M, Basik M.

BMC Cancer. 2015 Mar 15;15:130. doi: 10.1186/s12885-015-1117-0.

28.

Glycoproteomic comparison of clinical triple-negative and luminal breast tumors.

Hill JJ, Tremblay TL, Fauteux F, Li J, Wang E, Aguilar-Mahecha A, Basik M, O'Connor-McCourt M.

J Proteome Res. 2015 Mar 6;14(3):1376-88. doi: 10.1021/pr500987r. Epub 2015 Feb 16.

PMID:
25658377
29.

Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp SE, Trop I, Lisbona A, Wright FC, Younan RJ, Provencher L, Patocskai E, Omeroglu A, Robidoux A.

J Clin Oncol. 2015 Jan 20;33(3):258-64. doi: 10.1200/JCO.2014.55.7827. Epub 2014 Dec 1.

PMID:
25452445
30.

Chromosome-breakage genomic instability and chromothripsis in breast cancer.

Przybytkowski E, Lenkiewicz E, Barrett MT, Klein K, Nabavi S, Greenwood CM, Basik M.

BMC Genomics. 2014 Jul 9;15:579. doi: 10.1186/1471-2164-15-579.

31.

Testing devices or experimental systems? Cancer clinical trials take the genomic turn.

Nelson NC, Keating P, Cambrosio A, Aguilar-Mahecha A, Basik M.

Soc Sci Med. 2014 Jun;111:74-83. doi: 10.1016/j.socscimed.2014.04.008. Epub 2014 Apr 12.

PMID:
24768778
32.

Imiquimod in the treatment of breast cancer skin metastasis.

Henriques L, Palumbo M, Guay MP, Bahoric B, Basik M, Kavan P, Batist G.

J Clin Oncol. 2014 Mar 10;32(8):e22-5. doi: 10.1200/JCO.2012.46.4883. Epub 2014 Jan 13. No abstract available.

PMID:
24419128
33.

RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.

Keilty D, Buchanan M, Ntapolias K, Aleynikova O, Tu D, Li X, Shepherd L, Bramwell V, Basik M.

PLoS One. 2013 Dec 19;8(12):e81740. doi: 10.1371/journal.pone.0081740. eCollection 2013.

34.

Biopsies: next-generation biospecimens for tailoring therapy.

Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CM, Batist G.

Nat Rev Clin Oncol. 2013 Aug;10(8):437-50. doi: 10.1038/nrclinonc.2013.101. Epub 2013 Jun 25. Review. Erratum in: Nat Rev Clin Oncol. 2013 Nov;10(11):608.

PMID:
23799370
35.

Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine.

Diaz Z, Aguilar-Mahecha A, Paquet ER, Basik M, Orain M, Camlioglu E, Constantin A, Benlimame N, Bachvarov D, Jannot G, Simard MJ, Chabot B, Gologan A, Klinck R, Gagnon-Kugler T, Lespérance B, Samson B, Kavan P, Alcindor T, Dalfen R, Lan C, Chabot C, Buchanan M, Przybytkowski E, Qureshi S, Rousseau C, Spatz A, Têtu B, Batist G.

Mod Pathol. 2013 Nov;26(11):1413-24. doi: 10.1038/modpathol.2013.81. Epub 2013 Jun 7.

36.

Monoallelic chromatin conformation flanking long-range silenced domains in cancer-derived and normal cells.

Di Paola D, Raelson J, Rampakakis E, Basik M, Zannis-Hadjopoulos M, Bradley WE.

PLoS One. 2013 May 16;8(5):e63190. doi: 10.1371/journal.pone.0063190. Print 2013.

37.

Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer.

Déry MA, Jodoin J, Ursini-Siegel J, Aleynikova O, Ferrario C, Hassan S, Basik M, LeBlanc AC.

Breast Cancer Res. 2013 Mar 12;15(2):R22. doi: 10.1186/bcr3398.

38.

Ultradense array CGH and discovery of micro-copy number alterations and gene fusions in the cancer genome.

Przybytkowski E, Aguilar-Mahecha A, Nabavi S, Tonellato PJ, Basik M.

Methods Mol Biol. 2013;973:15-38. doi: 10.1007/978-1-62703-281-0_2.

39.

Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues.

Gottlieb B, Alvarado C, Wang C, Gharizadeh B, Babrzadeh F, Richards B, Batist G, Basik M, Beitel LK, Trifiro M.

Hum Mutat. 2013 Apr;34(4):610-8. doi: 10.1002/humu.22287. Epub 2013 Mar 8.

PMID:
23377847
40.

Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration.

Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M, Wrana JL.

Cell. 2012 Dec 21;151(7):1542-56. doi: 10.1016/j.cell.2012.11.024.

41.

The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines.

Aguilar-Mahecha A, Kuzyk MA, Domanski D, Borchers CH, Basik M.

PLoS One. 2012;7(6):e38290. doi: 10.1371/journal.pone.0038290. Epub 2012 Jun 6.

42.

Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes.

Tabariès S, Dupuy F, Dong Z, Monast A, Annis MG, Spicer J, Ferri LE, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM.

Mol Cell Biol. 2012 Aug;32(15):2979-91. doi: 10.1128/MCB.00299-12. Epub 2012 May 29.

43.

Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation.

Duhamel S, Hébert J, Gaboury L, Bouchard A, Simon R, Sauter G, Basik M, Meloche S.

Cancer Res. 2012 Feb 1;72(3):626-35. doi: 10.1158/0008-5472.CAN-11-2126.

44.

Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.

Ha KC, Lalonde E, Li L, Cavallone L, Natrajan R, Lambros MB, Mitsopoulos C, Hakas J, Kozarewa I, Fenwick K, Lord CJ, Ashworth A, Vincent-Salomon A, Basik M, Reis-Filho JS, Majewski J, Foulkes WD.

BMC Med Genomics. 2011 Oct 27;4:75. doi: 10.1186/1755-8794-4-75.

45.

Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies.

Batist G, Wu JH, Spatz A, Miller WH Jr, Cocolakis E, Rousseau C, Diaz Z, Ferrario C, Basik M.

Front Pharmacol. 2011 Oct 5;2:59. doi: 10.3389/fphar.2011.00059. eCollection 2011.

46.

Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155.

Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK.

Nat Med. 2011 Sep 25;17(10):1275-82. doi: 10.1038/nm.2459. Erratum in: Nat Med. 2011 Nov;17(11):1521. Nat Med. 2011 Oct;17(10):2 p following 1282.

47.

An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.

Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, Hassan S, Edgren H, Kallioniemi O, Aleynikova O, Przybytkowski E, Malcolm K, Mousses S, Tonin PN, Basik M.

Oncogene. 2012 Apr 19;31(16):2090-100. doi: 10.1038/onc.2011.386. Epub 2011 Sep 5.

PMID:
21892209
48.

Knockdown of RARB2 identifies a dual role in cancer.

Pappas JJ, Toulouse A, Basik M, Lévesque L, Bradley WE.

Genes Chromosomes Cancer. 2011 Sep;50(9):700-14. doi: 10.1002/gcc.20892. Epub 2011 Jun 2.

PMID:
21638515
49.

Discordant phenotypes in a mother and daughter with mosaic supernumerary ring chromosome 19 explained by a de novo 7q36.2 deletion and 7p22.1 duplication.

Argiropoulos B, Carter M, Brierley K, Hare H, Bouchard A, Al-Hertani W, Ryan SR, Reid J, Basik M, McGowan-Jordan J, Graham GE.

Am J Med Genet A. 2011 Apr;155A(4):885-91. doi: 10.1002/ajmg.a.33918. Epub 2011 Mar 17.

PMID:
21416596
50.

The use of ultra-dense array CGH analysis for the discovery of micro-copy number alterations and gene fusions in the cancer genome.

Przybytkowski E, Ferrario C, Basik M.

BMC Med Genomics. 2011 Jan 27;4:16. doi: 10.1186/1755-8794-4-16.

Supplemental Content

Support Center